Hunting down factor VIII in the immunopeptidome.

Area of Science:

• Immunology
• Molecular Biology
• Protein Chemistry

Background:

• Major histocompatibility complex class II (MHCII) restricted peptide presentation is vital for CD4+ T cell selection and proliferation.
• While beneficial for vaccination, the emergence of antigen-specific CD4+ T cells against therapeutic proteins like Factor VIII (FVIII) is undesirable.
• Understanding FVIII uptake, processing, and presentation by antigen-presenting cells (APCs) is critical for managing immune responses in hemophilia A patients.

Purpose of the Study:

• To review current knowledge on FVIII-derived peptides presented on MHCII.
• To discuss the implications of these findings for inhibitor development in hemophilia A.
• To elucidate the mechanisms of FVIII presentation by APCs.

Main Methods:

• Identification of FVIII peptides recognized by CD4+ T cells using MHCII tetramers and peptide-induced proliferation assays.
• Analysis of naturally presented FVIII-derived peptides by pulsing immature dendritic cells with FVIII.
• Utilizing HLA-DRB1(∗)15 transgenic mice to identify HLA-DRB1(∗)15 restricted CD4+ T cells reactive to human FVIII.

Main Results:

• Multiple receptors have been implicated in FVIII uptake by APCs, with the C1 domain of FVIII being a key determinant.
• Previous knowledge of FVIII-presented peptides on MHCII was limited.
• Recent studies have identified specific FVIII peptide sequences recognized by CD4+ T cells.

Conclusions:

• This review summarizes the current understanding of FVIII-derived peptides presented on MHCII.
• The findings are relevant to understanding inhibitor development in hemophilia A patients.
• Further research into FVIII presentation mechanisms can inform therapeutic strategies.